Welcome to our dedicated page for Biorestorative Therapies SEC filings (Ticker: BRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioRestorative Therapies, Inc. (NASDAQ: BRTX) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. BioRestorative is a biotechnology issuer that develops adult stem cell-based therapies and products, and its filings offer detailed insight into the disc/spine, metabolic, and BioCosmeceutical programs that it highlights in its public communications.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which BioRestorative identifies in its S-1 registration statement as being incorporated by reference. These reports discuss risk factors, management’s discussion and analysis, and financial statements related to its clinical-stage BRTX-100 program for degenerative disc disease, the ThermoStem® metabolic platform targeting obesity and metabolic disorders, and its commercial BioCosmeceutical activities.
Investors can also examine current reports on Form 8-K that BioRestorative files to describe material events. Recent examples include disclosures about a registered direct offering of common stock with concurrent private placement of unregistered warrants, the use of proceeds for BRTX-100 clinical trials and ThermoStem® preclinical research, stockholder meeting results, and the release of quarterly financial results and corporate presentations.
In addition, this page surfaces registration statements such as Form S-1 and Form S-3, where BioRestorative outlines the terms of offerings, the status of its common stock on the NASDAQ Capital Market, and the documents incorporated by reference. Users interested in executive compensation, governance, and voting matters can consult the company’s definitive proxy statement on Schedule 14A.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand topics such as capital raises, clinical program disclosures, and stock incentive plan changes. Real-time updates from EDGAR ensure that new BRTX filings, including Forms 3, 4, and 5 related to insider transactions when available, are added promptly for ongoing analysis.
BioRestorative Therapies, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The release also provided a business update and included details for a conference call to discuss the quarter. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
The filing states that the information furnished is summary information to be considered in the context of the Company’s SEC filings and other public announcements. The Company expressly furnishes the press release (it is not being filed for purposes of Section 18 of the Exchange Act) and does not incorporate the press release by reference into other registration statements unless specifically stated.
BioRestorative Therapies, Inc. is soliciting proxies for its 2025 Annual Meeting to be held September 18, 2025, where stockholders will vote on two Class II director nominees, an amendment to increase the 2021 Stock Incentive Plan authorized shares from 6,850,000 to 9,850,000, ratification of CBIZ CPAs P.C. as the independent auditor for fiscal 2025, and a non-binding advisory vote on executive compensation. Only stockholders of record as of July 31, 2025 may vote; there were 7,978,117 common shares and 1,398,158 Series B preferred shares outstanding on that date.
Executive pay highlights: CEO Lance Alstodt’s 2024 total reported compensation was $1,314,583 (compensation actually paid $1,202,070). Pay-versus-performance figures show cumulative TSR on a $100 investment of $32.95 (2024) with net losses of $(8,979,381) in 2024, $(10,417,704) in 2023 and $(13,222,296) in 2022. The proxy discloses identified material weaknesses in internal control over financial reporting and the auditor transition from Marcum LLP to CBIZ CPAs following Marcum’s attest business acquisition.